¨
|
For the transition period from to .
|
Delaware
(State or other jurisdiction of
incorporation or organization)
|
94-1620407
(I.R.S. employer
identification number)
|
468 N. Camden Dr., 2nd Floor, Beverly Hills, CA 90210
(Address of principal executive offices and zip code)
(310) 860-5184
(Registrant’s telephone number, including area code)
|
Large accelerated filer ¨
|
Accelerated filer ¨
|
Non-accelerated filer ¨ (Do not check if a smaller reporting company)
|
Smaller reporting company þ
|
PART I FINANCIAL INFORMATION
|
Page
|
||||
Item 1.
|
Financial Statements
|
||||
Item 2.
|
25 | ||||
Item 3.
|
30 | ||||
Item 4.
|
30 | ||||
PART II OTHER INFORMATION
|
|||||
Item 1.
|
31 | ||||
Item 1A.
|
31 | ||||
Item 2.
|
31 | ||||
Item 3.
|
31 | ||||
Item 4.
|
[RESERVED]
|
31 | |||
Item 5.
|
31 | ||||
Item 6.
|
32 | ||||
33 |
September 30, 2011
|
December 31, 2010
|
||||||
(unaudited)
|
|||||||
ASSETS
|
|||||||
Current Assets:
|
|||||||
Cash and cash equivalents
|
$
|
0
|
$
|
54,000
|
|||
Prepaid expenses
|
343,000
|
83,000
|
|||||
Total Current Assets
|
343,000
|
137,000
|
|||||
Patents, net
|
28,000
|
48,000
|
|||||
Total Other Assets
|
28,000
|
48,000
|
|||||
TOTAL ASSETS
|
$
|
371,000
|
$
|
185,000
|
|||
LIABILITIES AND STOCKHOLDERS’ DEFICIT
|
|||||||
Current Liabilities:
|
|||||||
Accounts payable
|
$
|
974,000
|
$
|
625,000
|
|||
Accrued interest
|
1,614,000
|
1,439,000
|
|||||
Accrued expenses
|
557,000
|
414,000
|
|||||
Warrant liability
|
290,000
|
1,012,000
|
|||||
Demand notes payable, net of discount of $53,000 and $0
|
198,000
|
205,000
|
|||||
Convertible debentures, net of discount of $0 and $250,000, current portion
|
505,000
|
415,000
|
|||||
Convertible debentures
|
1,139,000
|
1,544,000
|
|||||
Total Current Liabilities
|
5,277,000
|
5,654,000
|
|||||
Stockholders’ Deficit:
|
|||||||
Convertible preferred stock - $0.001 par value; 15,000,000 shares authorized:
|
|||||||
Series C - 96,230 and 96,230 shares issued and outstanding at September 30, 2011 and December 31, 2010, respectively
|
1,000
|
1,000
|
|||||
Series H – 25,000 and 25,000 shares issued and outstanding at September 30, 2011 and December 31, 2010, respectively
|
—
|
—
|
|||||
Series I – 1,666,667 and 1,666,667 shares issued and outstanding at September 30, 2011 and December 31, 2010, respectively
|
2,000
|
2,000
|
|||||
Common stock - $0.001 par value; 600,000,000 shares authorized; 238,622,616 and 149,571,976 shares issued and outstanding at September 30, 2011 and December 31, 2010, respectively
|
239,000
|
149,000
|
|||||
Additional paid-in capital
|
77,509,000
|
74,474,000
|
|||||
Accumulated deficit
|
(82,657,000
|
)
|
(80,095,000
|
)
|
|||
Total Stockholders’ Deficit
|
(4,906,000
|
)
|
(5,469,000
|
)
|
|||
TOTAL LIABILITIES AND STOCKHOLDERS’ DEFICIT
|
$
|
371,000
|
$
|
185,000
|
Three Months Ended September 30,
|
Nine Months Ended September 30,
|
|||||||||||||||
2011
|
2010
|
2011
|
2010
|
|||||||||||||
(Unaudited)
|
(Unaudited)
|
(Unaudited)
|
(Unaudited)
|
|||||||||||||
Revenue:
|
||||||||||||||||
Product revenues
|
$ | 2,000 | — | $ | 23,000 | — | ||||||||||
License revenues
|
— | — | — | — | ||||||||||||
TOTAL REVENUE
|
2,000 | — | 23,000 | — | ||||||||||||
Cost of Product Revenue
|
8,000 | — | 48,000 | — | ||||||||||||
Gross profit (loss)
|
(6,000 | ) | — | (25,000 | ) | — | ||||||||||
Operating Expenses:
|
||||||||||||||||
Research and development
|
— | 66,000 | 49,000 | 160,000 | ||||||||||||
Selling, general and administrative
|
535,000 | 588,000 | 2,806,000 | 1,810,000 | ||||||||||||
Total operating expenses
|
535,000 | 654,000 | 2,855,000 | 1,970,000 | ||||||||||||
Loss from Operations
|
(541,000 | ) | (654,000 | ) | (2,880,000 | ) | (1,970,000 | ) | ||||||||
Change in value of warrant and derivative liabilities
|
681,000 | 44,000 | 783,000 | 59,000 | ||||||||||||
Interest expense/income
|
(117,000 | ) | (23,000 | ) | (465,000 | ) | (422,000 | ) | ||||||||
Total Other Income (Expense)
|
564,000 | 21,000 | 318,000 | (363,000 | ) | |||||||||||
Income (loss) before provision for income taxes
|
23,000 | (633,000 | ) | (2,562,000 | ) | (2,333,000 | ) | |||||||||
Provision for income taxes
|
— | — | — | — | ||||||||||||
Net income (loss)
|
$ | 23,000 | $ | (633,000 | ) | $ | (2,562,000 | ) | $ | (2,333,000 | ) | |||||
Earnings (Loss) Per Share, basic and diluted
|
$ | 0.00 | $ | 0.01 | $ | (0.01 | ) | $ | (0.02 | ) | ||||||
Weighted Average Shares Outstanding, basic
and diluted
|
213,511,550 | 124,506,306 | 183,038,141 | 100,054,520 |
Preferred Stock
|
Common Stock
|
Additional Paid-in
|
Accumulated
|
|||||||||||||||
Shares
|
Amount
|
Shares
|
Amount
|
Capital
|
Deficit
|
|||||||||||||
Balance, December 31, 2009
|
121,230
|
$
|
1,000
|
67,040,809
|
$
|
67,000
|
$
|
71,308,000
|
$
|
(77,100,000
|
)
|
|||||||
Issuance of stock options
|
|
|
149,000
|
|||||||||||||||
Issuance of Preferred stock Series I
|
1,666,667
|
2,000
|
248,000
|
|||||||||||||||
Issuance of common stock for services
|
3,984,723
|
4,000
|
674,000
|
|||||||||||||||
Conversion of debt
|
75,047,995
|
75,000
|
2,075,000
|
|||||||||||||||
Exercise of warrants
|
3,398,449
|
3,000
|
23,000
|
|||||||||||||||
Exercise of stock options
|
100,000
|
20,000
|
||||||||||||||||
Deemed dividend
|
(23,000)
|
|||||||||||||||||
Net loss
|
(2,995,000
|
)
|
||||||||||||||||
Balance, December 31, 2010
|
1,787,897
|
$
|
3,000
|
149,571,976
|
$
|
149,000
|
$
|
74,474,000
|
$
|
(80,095,000
|
)
|
|||||||
Issuance of stock options
|
|
126,000
|
||||||||||||||||
Issuance of common stock for services
|
10,271,366
|
11,000
|
1,587,000
|
|||||||||||||||
Conversion of debt
|
61,831,683
|
62,000
|
1,082,000
|
|||||||||||||||
Exercise of warrants
|
14,169,813
|
14,000
|
||||||||||||||||
Issuance of common stock for joint venture
|
2,777,778
|
3,000
|
240,000
|
|||||||||||||||
Net loss
|
(2,562,000)
|
|||||||||||||||||
Balance at September 30, 2011
|
1,787,897
|
$3,000
|
238,622,616
|
$
|
239,000
|
$
|
77,509,000
|
$
|
(82,657,000
|
)
|
Nine months Ended
September 30,
|
||||||||
2011
(unaudited)
|
2010
(unaudited)
|
|||||||
CASH FLOWS FROM OPERATING ACTIVITIES:
|
||||||||
Net loss
|
$
|
(2,562,000
|
)
|
$
|
(2,333,000
|
)
|
||
Adjustments to reconcile net loss to net cash used in operating activities:
|
||||||||
Amortization of intangible assets
|
20,000
|
21,000
|
||||||
Stock compensation expense for options and warrants issued to employees and non-employees
|
126,000
|
569,000
|
||||||
Issuance of shares for services
|
1,597,000
|
—
|
||||||
Amortization of debt discounts
|
306,000
|
369,000
|
||||||
Change in value of warrant and derivative liabilities
|
(783,000
|
)
|
59,000
|
|||||
Changes in operating assets and liabilities:
|
||||||||
Prepaid expense and other current assets
|
(10,000
|
)
|
(78,000
|
)
|
||||
Accounts payable and accrued expenses
|
667,000
|
235,000
|
||||||
Net cash used in operating activities
|
(639,000
|
)
|
(1,158,000
|
)
|
||||
CASH FLOWS FROM FINANCING ACTIVITIES:
|
||||||||
Proceeds from the exercise of options and warrants
|
14,000
|
46,000
|
||||||
Proceeds from notes payable
|
621,000
|
—
|
||||||
Repayment of notes payable
|
(50,000
|
)
|
—
|
|||||
Net cash provided by financing activities
|
585,000
|
46,000
|
||||||
NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS
|
(54,000
|
)
|
(1,112,000
|
)
|
||||
CASH AND CASH EQUIVALENTS - Beginning of period
|
54,000
|
1,293,000
|
||||||
CASH AND CASH EQUIVALENTS - End of period
|
$
|
—
|
$
|
181,000
|
|
·
|
Level 1 inputs to the valuation methodology are quoted prices (unadjusted) for identical assets or liabilities in active markets. The Company’s Level 1 assets include cash equivalents, primarily institutional money market funds, whose carrying value represents fair value because of their short-term maturities of the investments held by these funds.
|
|
·
|
Level 2 inputs to the valuation methodology include quoted prices for similar assets and liabilities in active markets, and inputs that are observable for the asset or liability, either directly or indirectly, for substantially the full term of the financial instrument. The Company’s Level 2 liabilities consist of two liabilities arising from the issuance of a convertible debenture in 2006 and in accordance with EITF 00-19: a warrant liability for detachable warrants, as well as an accrued derivative liability for the beneficial conversion feature. These liabilities are remeasured on a quarterly basis. Fair value is determined using the Black-Scholes valuation model based on observable market inputs, such as share price data and a discount rate consistent with that of a government-issued security of a similar maturity.
|
|
·
|
Level 3 inputs to the valuation methodology are unobservable and significant to the fair value measurement.
|
Description
|
Level 1
|
Level 2
|
Level 3
|
|||||||||
Assets
|
||||||||||||
$
|
—
|
$
|
—
|
$
|
—
|
|||||||
Liabilities
|
||||||||||||
Warrant liability
|
—
|
290,000
|
—
|
September 30, 2011
|
December 31, 2010
|
|||||||
Capitalized patent costs
|
$ | 640,000 | $ | 640,000 | ||||
Accumulated amortization
|
(612,000 | ) | (592,000 | ) | ||||
$ | 28,000 | $ | 48,000 |
2011
|
$
|
23,000
|
|
2012
|
11,000
|
||
2013
|
4,000
|
||
2014
|
4,000
|
||
2015
|
4,000
|
|
·
|
0% Convertible Debentures in the principal amount of $2,000,000 due 24 months from the date of issuance (the “Debentures”), convertible into shares of the Company’s common stock at a per share conversion price equal to $0.05 per share;
|
|
·
|
Series A warrant to purchase such number of shares of the Company’s common stock equal to 50% of the principal amount invested by each investor (the “Class A Warrants” ) resulting in the issuance of Class A Warrants to purchase 20,000,000 shares of common stock of the Company.
|
|
·
|
Series B warrant to purchase such number of shares of the Company’s common stock equal to 50% of the principal amount invested by each investor (the “Class B Warrants”) resulting in the issuance of Class B Warrants to purchase 20,000,000 shares of common stock of the Company.
|
|
·
|
12% Convertible Debentures in the principal amount of $500,000 due April 15, 2012, convertible into shares of the Company’s common stock at a per share conversion price equal to $0.10 per share; and
|
|
·
|
Warrants to purchase 5,000,000 of shares of the Company’s common stock. The warrants are exercisable, on a cash or cashless basis, for up to two years from the date of issue at a per share exercise price equal to $0.15.
|
·
|
Ergo ARDS shall pay the following cash amounts to Dr. Repine upon the attainment of the following milestones:
|
(i)
|
Licensing the Assigned IP to a pharmaceutical company -- $1,000,000;
|
|
(ii)
|
Completion of Phase I Clinical Trial -- $250,000;
|
|
(iii)
|
Completion of Phase II Clinical Trial -- $1,000,000;
|
|
(iv)
|
Completion of pivotal Phase III Clinical Trial -- $1,500,000; and
|
|
(v)
|
Receipt of FDA Marketing approval -- $3,000,000
|
|
·
|
Ergo ARDS shall pay the following cash amounts to Dr. Repine upon the attainment of the following milestones:
|
(i)
|
Licensing the Assigned IP to, or entering into a distribution agreement with, a nutraceutical or similar company -- $100,000; and
|
|
(ii)
|
Gross sales of products utilizing Ergo in the Field – 5% of annual gross sales by the Company or any licensee or distributor (including Oxis).
|
·
|
As previously disclosed, the holder of the Series H Preferred is entitled to vote with the common stock, and is entitled to a number of votes equal to (i) the number of shares of common stock it can convert into (without any restrictions or limitations on such conversion), (ii) multiplied by 100.
|
·
|
The holder of the Series H Preferred cannot convert such preferred stock into shares of common stock if the holder and its affiliates after such conversion would own more than 9.9% of the Company’s then issued and outstanding shares of common stock.
|
·
|
The Series G Preferred contained a limitation that the holder of the Series G Preferred could not convert such preferred shares into more than 19.999% of the issued and outstanding shares of common stock without the approval of the stockholders if the rules of the principal market on which the common stock is traded would prohibit such a conversion. Since the rules of the Company’s principal market did not require such a limitation, that provision has been deleted.
|
Options Outstanding
|
Weighted Average Exercise Price
|
|||||||
Outstanding as of December 31, 2010
|
13,934,651
|
$
|
0.15
|
|||||
Granted
|
2,066,491
|
0.09
|
||||||
Forfeited
|
15,000
|
0.69
|
||||||
Exercised
|
—
|
—
|
||||||
Outstanding as of September 30, 2011
|
15,986,142
|
$
|
0.11
|
Warrants Outstanding
|
Weighted Average Exercise Price
|
|||||||
Outstanding as of December 31, 2010
|
80,041,252
|
$
|
0.07
|
|||||
Granted
|
6,882,500
|
0.13
|
||||||
Forfeited
|
4,316,636
|
0.07
|
||||||
Exercised
|
13,783,364
|
0.03
|
||||||
Outstanding as of September 30, 2011
|
68,823,752
|
$
|
0.09
|
·
|
On July 6, 2011 OXIS issued to Dr. Repine 2,777,778 shares of common stock (valued at $250,000) for various services relating to the terms of the consulting agreement;
|
·
|
OXIS agreed to issue to Dr. Repine additional shares of common stock valued at $50,000 upon completion of the first animal study and Dr. Repine’s delivery to Ergo ARDS of a summary presentation of the findings of the study; and
|
·
|
OXIS agreed to issue Dr. Repine additional shares of common stock valued at $100,000 upon the completion of such second animal study and Dr. Repine’s delivery to Ergo ARDS of a summary presentation of the findings of the study.
|
Three Months Ended September 30,
|
Nine Months September September 30,
|
|||||||||||||||||||||||
2011
|
2010
|
Increase from 2010
|
2011
|
2010
|
Increase from 2010
|
|||||||||||||||||||
Product revenues
|
$ | 2,000 | $ | 0 | $ | 2,000 | $ | 23,000 | $ | 0 | $ | 23,000 |
Three Months Ended September 30,
|
Nine Months Ended September 30,
|
|||||||||||||||||||||||
2011
|
2010
|
Increase from 2010
|
2011
|
2010
|
Increase from 2010
|
|||||||||||||||||||
Cost of product revenues
|
$ | 8,000 | $ | 0 | $ | 8,000 | $ | 48,000 | $ | 0 | $ | 48,000 | ||||||||||||
Three Months Ended September 30,
|
Nine Months Ended September 30,
|
|||||||||||||||||||||||
2011
|
2010
|
Increase from 2010
|
2011
|
2010
|
Increase from 2010
|
|||||||||||||||||||
Selling, general and administrative expenses
|
$ | 535,000 | $ | 588,000 | $ | (53,000 | ) | $ | 2,806,000 | $ | 1,811,000 | $ | 995,000 |
·
|
2,777,778 shares of Common Stock were issued as compensation an investment in a Joint Venture (having an aggregate value of $250,000
|
·
|
10,062,500 shares were issued to holders upon exercise of warrants (having an aggregate value of $10,063; and
|
·
|
16,024,000 shares were issued to holders upon conversion of $320,240 of convertible debentures and demand notes.
|
Exhibit Number
|
Description of Exhibit
|
31.1
|
Certification of Principal Executive Officer pursuant to Rule 13a-14 and Rule 15d-14(a), promulgated under the Securities and Exchange Act of 1934, as amended.
|
31.2
|
Certification of Principal Financial Officer pursuant to Rule 13a-14 and Rule 15d 14(a), promulgated under the Securities and Exchange Act of 1934, as amended.
|
32.1
|
Certification pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 (Chief Executive Officer).
|
32.2
|
Certification pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 (Chief Financial Officer).
|
OXIS International, Inc.
|
||||
November 21, 2011
|
By:
|
/s/ David Saloff
|
||
David Saloff
Chief Executive Officer (Principal Executive Officer)
|
||||
November 21, 2011
|
By:
|
/s/ David Saloff
|
||
David Saloff
Acting Chief Financial Officer (Principal Financial and Accounting Officer)
|
1.
|
I have reviewed this Quarterly Report on Form 10-Q of OXIS International, Inc;
|
2.
|
Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
|
3.
|
Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
|
4.
|
I am responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
|
|
a)
|
Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under my supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
|
|
b)
|
Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under my supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
|
|
c)
|
Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report my conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
|
|
d)
|
Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
|
5.
|
I have disclosed, based on my most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
|
|
a)
|
All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
|
|
b)
|
Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.
|
Dated: November 21, 2011
|
By: /s/ David Saloff
|
David Saloff
|
|
Chief Executive Officer
|
1.
|
I have reviewed this Quarterly Report on Form 10-Q of OXIS International, Inc;
|
2.
|
Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
|
3.
|
Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
|
4.
|
I am responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
|
|
a)
|
Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under my supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
|
|
b)
|
Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under my supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
|
|
c)
|
Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report my conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
|
|
d)
|
Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
|
5.
|
I have disclosed, based on my most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
|
|
a)
|
All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
|
|
b)
|
Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.
|
Dated: November 21, 2011
|
By: /s/David Saloff
|
David Saloff
|
|
Acting Chief Financial Officer
|
Dated: November 21, 2011
|
By: /s/ David Saloff
|
David Saloff
|
|
Chief Executive Officer
|
Dated: November 21, 2011
|
By: /s/David Saloff
|
David Saloff
|
|
Acting Chief Financial Officer
|
Debt | 9 Months Ended | |||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Sep. 30, 2011 | ||||||||||||||||||||||
Notes to Financial Statements | ||||||||||||||||||||||
Debt |
Convertible debentures
On October 25, 2006, the Company entered into a securities purchase agreement (Purchase Agreement) with four accredited investors (the Purchasers). In conjunction with the signing of the Purchase Agreement, the Company issued secured convertible debentures (Debentures) and Series A, B, C, D, and E common stock warrants (Warrants) to the Purchasers, and the parties also entered into a registration rights agreement and a security agreement (collectively, the Transaction Documents).
Pursuant to the terms of the Purchase Agreement, the Company issued the Debentures in an aggregate principal amount of $1,694,250 to the Purchasers. The Debentures are subject to an original issue discount of 20.318% resulting in proceeds to the Company of $1,350,000 from the transaction. The Debentures were due on October 25, 2008. The Debentures are convertible, at the option of the Purchasers, at any time, into shares of common stock at $0.35 per share, as adjusted pursuant to a full ratchet anti-dilution provision (the Conversion Price). Beginning on the first of the month beginning February 1, 2007, the Company was required to amortize the Debentures in equal installments on a monthly basis resulting in a complete repayment by the maturity date (the Monthly Redemption Amounts). The Monthly Redemption Amounts can be paid in cash or in shares, subject to certain restrictions. If the Company chooses to make any Monthly Redemption Amount payment in shares of common stock, the price per share is the lesser of the Conversion Price then in effect and 85% of the weighted average price for the 10 trading days prior to the due date of the Monthly Redemption Amount.
The Company has not made required monthly redemption payments beginning on February 1, 2007 to purchasers of debentures issued in October 2006. Pursuant to the provisions of the Secured Convertible Debentures, such non-payment is an event of default. Penalty interest accrues on any unpaid redemption balance at an interest rate equal to the lesser of 18% per annum or the maximum rate permitted by applicable law until such amount is paid in full. Upon an event of default, each purchaser has the right to accelerate the cash repayment of at least 130% of the outstanding principal amount of the debenture plus accrued but unpaid liquidated damages and interest. If the Company continued to fail to make such payments in full, the purchasers have the right sell substantially all of the Companys assets pursuant to their security interest to satisfy any such unpaid balance. The Purchasers have a right of first refusal to participate in up to 100% of any future financing undertaken by the Company until the later of the date that the Debentures are no longer outstanding and the one year anniversary of the effective date of the registration statement. The Company was restricted from issuing shares of common stock or instruments convertible into common stock for 90 days after the effective date of the registration statement with certain exceptions. The Company is also prohibited from effecting any subsequent financing involving a variable rate transaction until such time as no Purchaser holds any of the Debentures. In addition, until such time as any Purchaser holds any of the securities issued in the Debenture transaction, if the Company issues or sells any common stock or instruments convertible into common stock which a Purchaser reasonably believes is on terms more favorable to such investors than the terms pursuant to the Transaction Documents, the Company is obligated to amend the terms of the Transaction Documents to such Purchaser the benefit of such better terms.
On October 25, 2006, in conjunction with the signing of the Purchase Agreement, the Company issued to the Purchasers five year Series A Warrants to purchase an aggregate of 2,420,357 shares of common stock at an initial exercise price of $0.35 per share, one year Series B Warrants to purchase 2,420,357 shares of common stock at an initial exercise price of $0.385 per share, and two year Series C Warrants to purchase an aggregate of 4,840,714 shares of common stock at an initial exercise price of $0.35 per share. In addition, the Company issued to the Purchasers Series D and E Warrants which become exercisable on a pro-rata basis only upon the exercise of the Series C Warrants. The six year Series D Warrants to purchase 2,420,357 shares of common stock have an initial exercise price of $0.35 per share. The six year Series E Warrants to purchase 2,420,357 shares of common stock have an initial exercise price of $0.385 per share. The initial exercise prices for each warrant are adjustable pursuant to a full ratchet anti-dilution provision and upon the occurrence of a stock split or a related event.
Pursuant to the registration rights agreement, the Company was obligated to file a registration statement covering the public resale of the shares underlying the Series A, B, C, D and E Warrants and the Debentures within 45 days of the closing of the transaction and cause the registration to be declared effective within 120 days of the closing date. The registration statement was filed and declared effective within the 120 of the closing date. Cash liquidated damages equal to 2% of the face value of the Debentures per month are payable to the purchasers for any failure to timely file or obtain an effective registration statement.
Pursuant to the Security Agreement, the Company agreed to grant the purchasers, pari passu, a security interest in substantially all of the Companys assets. The Company also agreed to pledge its respective ownership interests in its wholly-owned subsidiaries, OXIS Therapeutics, OXIS Isle of Man, and its partial subsidiary, BioCheck, Inc. In addition, OXIS Therapeutics and OXIS Isle of Man each provided a subsidiary guarantee to the Purchasers in connection with the transaction.
On April 9, 2008 and April 28, 2008, the Company was sent demand letters from one of the Purchasers, Bristol Investment Fund, Ltd. (Bristol) stating that the Company was in default under the Debentures due to lack of payment of required monthly principal installment payments starting in February 1, 2007. At the time of the April 9, 2008 letter, the Company and Bristol were in active negotiations on a proposed financing transaction which would provide the Company an opportunity to resolve the existing default under the Debentures. The proposed financing transaction was not accepted by all Purchasers and therefore was not executed. In the April 28, 2008 letter, Bristol demanded that the Company provide them with a definitive plan of action to resolve the existing default within three business days. Bristol did not make any specific demands for other costs, expenses or liquidated damages to date. On May 30, Cranshire Capital, LP (Cranshire), another Purchaser, sent a letter to the Company stating that the Company was in default on the Debentures and that Cranshire intended to seek all potential remedies. In response to the default letters received from Bristol and Cranshire, the Companys management had communicated its plan to pay all amounts due under the terms of the Debentures upon the sale of its 53% interest in BioCheck, Inc. and its research assay business prior to the maturity date of the Debentures on October 25, 2008 and referenced four non-binding letters of intent that it had received from potential purchasers. The indications of value contained in the letters of intent would provide, if closed, funds sufficient to pay off the Purchasers and additionally provide cash resources to support a business plan based on its nutraceutical and therapeutic assets. The Company was in active negotiations with the Purchasers aimed at resolving the existing default under the Debentures and avoiding the foreclosure sale.
On June 6, 2008, the Company received notification from Bristol that the collateral held under the Security Agreement would be sold to the highest qualified bidder on Thursday, June 19, 2008, and on June 19, 2008, the Company received a Notice of Disposition of Collateral from Bristol in which Bristol notified the Company that Bristol, acting as the agent for itself and the three other Purchasers, purchased certain assets held as collateral under the security agreement (referred to in this report as the Security Agreement). Bristol purchased 111,025 shares of common stock of BioCheck, Inc., the Companys majority owned subsidiary, on a credit bid of $50,000, and Bristol also purchased 1,000 shares of the capital stock of OXIS Therapeutics, Inc., a wholly owned subsidiary of OXIS, for a credit bid of $10,000. In December 2005, OXIS purchased the 111,025 shares of common stock of BioCheck, Inc. for $3,060,000. After crediting the aggregate amount of $60,000 to the aggregate amount due under the Debentures, plus fees and charges due through June 19, 2008, Bristol notified the Company that the Company remains obligated to the Purchasers in a deficiency in an aggregate amount of $2,688,000 as of June 19, 2008. As a result of the disposition of the collateral, the Company recorded a net loss aggregating $2,978,000.
During 2009, Bristol converted $177,900 of the principal amount for 17,790,000 shares of the Companys common stock.
During 2010, Bristol converted an additional $401,000 of the principal amount for 40,100,000 shares of the Companys common stock.
In February 2011, Bristol converted an additional $74,000 of the principal amount for 7,400,000 shares of the Companys common stock.
In March 2011, Bristol converted an additional $114,000 of the principal amount for 11,400,000 shares of the Companys common stock.
In April 2011, Bristol converted an additional $60,000 of the principal amount for 6,000,000 shares of the Companys common stock.
In May 2011, Bristol converted an additional $97,000 of the principal amount for 9,700,000 shares of the Companys common stock.
In September 2011, Bristol converted an additional $60,000 of the principal amount for 6,000,000 shares of the Companys common stock.
These convertible debentures do not meet the definition of a conventional convertible debt instrument since the debt is not convertible into a fixed number of shares. The Monthly Redemption Amounts can be paid with common stock at a conversion price that is a percentage of the market price; therefore the number of shares that could be required to be delivered upon net-share settlement is essentially indeterminate. Therefore, the convertible debenture is considered non-conventional, which means that the conversion feature must be bifurcated from the debt and shown as a separate derivative liability. This beneficial conversion liability has been calculated to be $690,000 on October 25, 2006. In addition, since the convertible debenture is convertible into an indeterminate number of shares of common stock, it is assumed that the Company could never have enough authorized and unissued shares to settle the conversion of the warrants issues in this transaction into common stock. Therefore, the warrants issued in connection with this transaction have a fair value of $2,334,000 at October 20, 2006. The value of the warrant was calculated using the Black-Scholes model using the following assumptions: Discount rate of 4.5%, volatility of 158% and expected term of 1 to 6 years. The fair value of the beneficial conversion feature and the warrant liability will be adjusted to fair value on each balance sheet date with the change being shown as a component of net loss.
The fair value of the beneficial conversion feature and the warrants at the inception of these convertible debentures were $690,000 and $2,334,000, respectively. The first $1,350,000 of these discounts has been shown as a discount to the convertible debentures which will be amortized over the term of the convertible debenture and the excess of $1,674,000 has been shown as financing costs in the accompanying statement of operations.
On October 1, 2009, the Company entered into a financing arrangement with several accredited investors (the October 2009 Investors), pursuant to which it sold various securities in consideration of a maximum aggregate purchase price of $2,000,000 (the October 2009 Financing). In connection with the October 2009 Financing, the Company issued the following securities to the October 2009 Investors:
· 0% Convertible Debentures in the principal amount of $2,000,000 due 24 months from the date of issuance (the “Debentures”), convertible into shares of the Company’s common stock at a per share conversion price equal to $0.05 per share; · Series A warrant to purchase such number of shares of the Company’s common stock equal to 50% of the principal amount invested by each investor (the “Class A Warrants” ) resulting in the issuance of Class A Warrants to purchase 20,000,000 shares of common stock of the Company. · Series B warrant to purchase such number of shares of the Company’s common stock equal to 50% of the principal amount invested by each investor (the “Class B Warrants”) resulting in the issuance of Class B Warrants to purchase 20,000,000 shares of common stock of the Company.
The full principal amount of the Debentures is due upon default under the terms of the Debentures. The Class A Warrants and Class B Warrants (collectively, the Warrants) are exercisable for up to five years from the date of issue at a per share exercise price equal to $0.0625 and $0.075 for the Class A Warrants and the Class B Warrants, respectively, on a cash or cashless basis. The Debentures and the Warrants are collectively referred to herein as the October 2009 Securities.
The Company and the October 2009 Investors agreed to place the proceeds from the October 2009 Financing in escrow. On a monthly basis, the Company and the nominee for the October 2009 Investors will send a joint statement, subject to settlement with existing creditors, to the escrow agent for the release of funds.
In connection with the sale of the October 2009 Securities by the Company, the Company and Bristol entered a Standstill and Forbearance Agreement, pursuant to which Bristol agreed to refrain and forbear from exercising certain rights and remedies with respect to (i) certain convertible debentures (the October 2006 Debentures), issued pursuant to that certain Securities Purchase Agreement, dated October 25, 2006 and (ii) demand notes (the Bridge Notes) issued by the Company on October 8, 2008, March 19, 2009, April 7, 2009, April 28, 2009, May 21, 2009 and June 25, 2009. In connection with the sale of the October 2009 Securities by the Company, the Company and Bristol have also entered into a waiver agreement (the Waiver Agreement) pursuant to which Bristol waived certain rights with respect to the October 2006 Debentures and Bridge Notes.
The conversion price and the exercise price will be subject to full ratchet anti-dilution adjustment in the event that the Company issues, after the closing date, common stock or common stock equivalents at a price per share less than the conversion price associated with the Debentures or the exercise price associated with the Warrants and to other normal and customary anti-dilution adjustment upon certain other events.
From the date hereof until such time the Debentures are no longer outstanding, if the Company effects a subsequent financing, the October 2009 Investors may elect, in their sole discretion, to exchange all or some of the October 2009 Debentures (but not the Warrants) for any securities or units issued in a subsequent financing on a $1.00 for $1.00 basis or to have any particular provisions of the subsequent financing legal documents apply to the documents utilized for the October 2009 Financing.
If at any time after the closing date, the Company shall determine to prepare and file with the Commission a registration statement relating to an offering for its own account or the account of others, then it shall include the shares of common stock underlying the Securities on such registration statement. The Company has also agreed to use its best efforts to take the most efficient actions (either by Proxy or Information Statement, if qualified) to ensure that the Company at all times after 30 days from closing will have reserved a sufficient number of authorized shares such that all of the shares of common stock issuable upon conversion or exercise of the Debentures and the Warrants can receive valid, authorized shares of common stock upon any conversion or exercise.
The October 2009 Investors have contractually agreed to restrict their ability to convert the Debentures and exercise the Warrants and receive shares of our common stock such that the number of shares of the Company common stock held by an October 2009 Investor and its affiliates after such conversion or exercise does not exceed 4.9% of the Companys then issued and outstanding shares of common stock.
During 2010, Investors converted $1,335,000 of the principal amount for 26,700,000 shares of the Companys common stock.
In March 2011, Investors converted an additional $40,000 of the principal amount for 800,000 shares of the Companys common stock.
In April 2011, Investors converted $350,000 of the principal amount for 7,000,000 shares of the Companys common stock.
In June 2011, Investors converted $20,000 of the principal amount for 400,000 shares of the Companys common stock.
In September 2011, Investors converted $200,000 of the principal amount for 4,000,000 shares of the Companys common stock.
On June 1, 2011, the Company entered into a financing arrangement with several accredited investors (the June 2011 Investors), pursuant to which it sold various securities in consideration of a maximum aggregate purchase price of $500,000 (the June 2011 Financing). In connection with the June 2011 Financing, the Company issued the following securities to the June 2011 Investors:
· 12% Convertible Debentures in the principal amount of $500,000 due April 15, 2012, convertible into shares of the Company’s common stock at a per share conversion price equal to $0.10 per share; and · Warrants to purchase 5,000,000 of shares of the Company’s common stock. The warrants are exercisable, on a cash or cashless basis, for up to two years from the date of issue at a per share exercise price equal to $0.15.
The Debentures and the Warrants are collectively referred to herein as the June 2011 Securities.
Demand Notes
On October 25, 2008, the Company entered into a demand note payable in the principal sum of $25,000. Interest shall accrue on the outstanding principal balance of this note from and after the date hereof at the rate of 10% per annum. Interest shall be calculated on the basis of a 360-day year, and shall be charged on the principal outstanding from time to time for the actual number of days elapsed. The Borrower shall pay the holder all accrued interest on the Maturity Date. At any time while this Note is outstanding, the holder may convert any portion of this Note that is outstanding, whether such portion represents principal or interest, into shares of common stock of the Company at a price equal to the lesser of (i) $0.01 and (ii) 60% of the average of the three (3) lowest trading prices occurring at any time during the twenty (20) trading days preceding the date that the Holder notifies the Company that it elects to effectuate a conversion. The Company must deliver the Conversion Shares to the holder no later than the third (3rd) business day after the Conversion Date Borrower shall pay the entire outstanding principal balance under this Note, together with all accrued and unpaid interest thereon , at anytime, in the Borrowers sole discretion, on or before the maturity date without penalty.
Simultaneously with the issuance of this note, the Company issued to the holder a warrant to purchase such number of shares of common stock of the Company equal to the number of conversion shares issuable upon full conversion of the principal amount of this note at a price equal to the lesser of (i) $0.01 and (ii) 60% of the average of the three (3) lowest trading prices occurring at any time during the 20 trading days preceding the issue date of this note.
On March 19, 2009, the Company entered into a convertible demand promissory note with Bristol Investment Fund, Ltd., pursuant to which Bristol purchased an aggregate principal amount of $12,500 of convertible demand promissory notes for an aggregate purchase price of $10,000. The Bristol Note will be convertible at the option of the holder at any time into shares of common stock, at a price equal to the lesser of (i) $0.01 and (ii) 60% of the average of the three (3) lowest trading prices occurring at any time during the twenty (20) trading days preceding the date that Bristol notifies the Company that it elects to effectuate a conversion.
Simultaneously with the issuance of the Bristol Note, the Company issued Bristol a warrant to purchase such number of shares of common stock of the Company equal to the number of Conversion Shares issuable upon full conversion of the principal amount of the Bristol Note at a price equal to the lesser of (i) $0.01 and (ii) 60% of the average of the three (3) lowest trading prices occurring at any time during the 20 trading days preceding the issue date of the Bristol Note (the Exercise Price). Bristol may exercise the Warrant on a cashless basis if the shares of common stock underlying the Warrant are not then registered pursuant to an effective registration statement. In the event Bristol exercises the Warrant on a cashless basis, we will not receive any proceeds.
On April 7, 2009, the Company entered into a convertible demand promissory note with Bristol Investment Fund, Ltd, pursuant to which Bristol purchased an aggregate principal amount of $156,875 of convertible demand promissory notes for an aggregate purchase price of $125,000. The Bristol Note will be convertible at the option of the holder at any time into shares of common stock, at a price equal to the lesser of (i) $0.01 and (ii) 60% of the average of the three (3) lowest trading prices occurring at any time during the twenty (20) trading days preceding the date that Bristol notifies the Company that it elects to effectuate a conversion.
Simultaneously with the issuance of the Bristol Note, the Company issued Bristol a warrant to purchase such number of shares of common stock of the Company equal to the number of Conversion Shares issuable upon full conversion of the principal amount of the Bristol Note at a price equal to the lesser of (i) $0.01 and (ii) 60% of the average of the three (3) lowest trading prices occurring at any time during the 20 trading days preceding the issue date of the Bristol Note (the Exercise Price). Bristol may exercise the Warrant on a cashless basis if the shares of common stock underlying the Warrant are not then registered pursuant to an effective registration statement. In the event Bristol exercises the Warrant on a cashless basis, we will not receive any proceeds.
On April 28, 2009, the Company entered into a convertible demand promissory note with Bristol Investment Fund, Ltd. Pursuant to which Bristol purchased an aggregate principal amount of $28,865 of convertible demand promissory notes for an aggregate purchase price of $23,000. The Bristol Note will be convertible at the option of the holder at any time into shares of common, at a price equal to the lesser of (i) $0.01 and (ii) 60% of the average of the three (3) lowest trading prices occurring at any time during the twenty (20) trading days preceding the date that Bristol notifies the Company that it elects to effectuate a conversion.
Simultaneously with the issuance of the Bristol Note, the Company issued Bristol a warrant to purchase such number of shares of common stock of the Company equal to the number of Conversion Shares issuable upon full conversion of the principal amount of the Bristol Note at a price equal to the lesser of (i) $0.01 and (ii) 60% of the average of the three (3) lowest trading prices occurring at any time during the 20 trading days preceding the issue date of the Bristol Note (the Exercise Price). Bristol may exercise the Warrant on a cashless basis if the shares of common stock underlying the Warrant are not then registered pursuant to an effective registration statement. In the event Bristol exercises the Warrant on a cashless basis, we will not receive any proceeds.
On May 15, 2009, the Company entered into a convertible demand promissory note with Bristol Capital, LLC for certain consulting services totaling $100,000. The note does not provide for any interest and is due upon demand by the holder. The Bristol Note will be convertible at the option of the holder at any time into shares of common stock, at a price equal to the lesser of (i) $0.01 and (ii) 60% of the average of the three (3) lowest trading prices occurring at any time during the twenty (20) trading days preceding the date that Bristol notifies the Company that it elects to effectuate a conversion.
On May 21, 2009, the Company entered into a convertible demand promissory note with Bristol Investment Fund, Ltd., pursuant to which Bristol purchased an aggregate principal amount of $31,375 of convertible demand promissory notes for an aggregate purchase price of $25,000. The Bristol Note will be convertible at the option of the holder at any time into shares of common stock, at a price equal to the lesser of (i) $0.01 and (ii) 60% of the average of the three (3) lowest trading prices occurring at any time during the twenty (20) trading days preceding the date that Bristol notifies the Company that it elects to effectuate a conversion.
Simultaneously with the issuance of the Bristol Note, the Company issued Bristol a warrant to purchase such number of shares of common stock of the Company equal to the number of Conversion Shares issuable upon full conversion of the principal amount of the Bristol Note at a price equal to the lesser of (i) $0.01 and (ii) 60% of the average of the three (3) lowest trading prices occurring at any time during the 20 trading days preceding the issue date of the Bristol Note (the Exercise Price). Bristol may exercise the Warrant on a cashless basis if the shares of common stock underlying the Warrant are not then registered pursuant to an effective registration statement. In the event Bristol exercises the Warrant on a cashless basis, we will not receive any proceeds.
On June 22, 2009, the Company entered into a convertible demand promissory note with Theorem Group (Theorem) pursuant to which Theorem purchased an aggregate principal amount of $31,375 of convertible demand promissory notes for an aggregate purchase price of $25,000. The Theorem Note will be convertible at the option of the holder at any time into shares of common stock, at a price equal to the lesser of (i) $0.01 and (ii) 60% of the average of the three (3) lowest trading prices occurring at any time during the twenty (20) trading days preceding the date that Theorem notifies the Company that it elects to effectuate a conversion.
Simultaneously with the issuance of the Theorem Note, the Company issued Theorem a warrant to purchase such number of shares of common stock of the Company equal to the number of Conversion Shares issuable upon full conversion of the principal amount of the Theorem Note at a price equal to the lesser of (i) $0.01 and (ii) 60% of the average of the three (3) lowest trading prices occurring at any time during the 20 trading days preceding the issue date of the Theorem Note (the Exercise Price). Theorem may exercise the Warrant on a cashless basis if the shares of common stock underlying the Warrant are not then registered pursuant to an effective registration statement. In the event Theorem exercises the Warrant on a cashless basis, we will not receive any proceeds.
On December 1, 2009, Theorem sold the note to NetCapital. In December 2009, NetCapital converted $24,000 of the principal for 2,400,000 shares of the Companys common stock.
In January 2010, NetCapital converted the remainder $7,375 of principal amount for an additional 737,500 shares of the Companys common stock.
On June 25, 2009, the Company entered into a convertible demand promissory note with Bristol Investment Fund, Ltd., pursuant to which Bristol purchased an aggregate principal amount of $31,375 of convertible demand promissory notes for an aggregate purchase price of $25,000. The Bristol Note will be convertible at the option of the holder at any time into shares of common stock, at a price equal to the lesser of (i) $0.01 and (ii) 60% of the average of the three (3) lowest trading prices occurring at any time during the twenty (20) trading days preceding the date that Bristol notifies the Company that it elects to effectuate a conversion.
Simultaneously with the issuance of the Bristol Note, the Company issued Bristol a warrant to purchase such number of shares of common stock of the Company equal to the number of Conversion Shares issuable upon full conversion of the principal amount of the Bristol Note at a price equal to the lesser of (i) $0.01 and (ii) 60% of the average of the three (3) lowest trading prices occurring at any time during the 20 trading days preceding the issue date of the Bristol Note (the Exercise Price). Bristol may exercise the Warrant on a cashless basis if the shares of common stock underlying the Warrant are not then registered pursuant to an effective registration statement. In the event Bristol exercises the Warrant on a cashless basis, we will not receive any proceeds.
During 2010, Bristol converted $50,000 of the principal amounts for 5,000,000 shares of the Companys common stock.
On February 7, 2011 the Company entered into a convertible demand promissory note with Bristol Investment Fund, Ltd., pursuant to which Bristol purchased an aggregate principal amount of $31,375 of convertible demand promissory notes for an aggregate purchase price of $25,000. The Bristol Note will be convertible at the option of the holder at any time into shares of common stock, at a price equal to $0.05.
Simultaneously with the issuance of the Bristol Note, the Company issued Bristol a Series A Warrant to purchase 313,750 shares of common stock of the Company at a per share exercise price of $0.0625, and a Series B Warrant to purchase 313,750 shares of common stock of the Company at a per share exercise price of $0.075. The Series A Warrants and Series B Warrants are exercisable for up to seven years from the date of issue. Bristol may exercise the Warrants on a cashless basis if the shares of common stock underlying the Warrants are not then registered pursuant to an effective registration statement. In the event Bristol exercises the Warrants on a cashless basis, we will not receive any proceeds.
On February 7, 2011 the Company entered into a convertible demand promissory note with Net Capital Partners, Inc., pursuant to which Net Capital purchased an aggregate principal amount of $31,375 of convertible demand promissory notes for an aggregate purchase price of $25,000. The Net Capital Note will be convertible at the option of the holder at any time into shares of common stock, at a price equal to $0.05.
Simultaneously with the issuance of the Net Capital Note, the Company issued Net Capital a Series A Warrant to purchase 313,750 shares of common stock of the Company at a per share exercise price of $0.0625, and a Series B Warrant to purchase 313,750 shares of common stock of the Company at a per share exercise price of $0.075. The Series A Warrants and Series B Warrants are exercisable for up to seven years from the date of issue. Net Capital may exercise the Warrants on a cashless basis if the shares of common stock underlying the Warrants are not then registered pursuant to an effective registration statement. In the event Net Capital exercises the Warrants on a cashless basis, we will not receive any proceeds.
On March 4, 2011 the Company entered into a convertible demand promissory note with Bristol Investment Fund, Ltd., pursuant to which Bristol purchased an aggregate principal amount of $31,375 of convertible demand promissory notes for an aggregate purchase price of $25,000. The Bristol Note will be convertible at the option of the holder at any time into shares of common stock, at a price equal to $0.05.
Simultaneously with the issuance of the Bristol Note, the Company issued Bristol a Series A Warrant to purchase 313,750 shares of common stock of the Company at a per share exercise price of $0.0625, and a Series B Warrant to purchase 313,750 shares of common stock of the Company at a per share exercise price of $0.075. The Series A Warrants and Series B Warrants are exercisable for up to seven years from the date of issue. Bristol may exercise the Warrants on a cashless basis if the shares of common stock underlying the Warrants are not then registered pursuant to an effective registration statement. In the event Bristol exercises the Warrants on a cashless basis, we will not receive any proceeds.
On April 4, 2011 the Company entered into a convertible demand promissory note with Net Capital Partners, Inc., pursuant to which Net Capital purchased an aggregate principal amount of $31,375 of convertible demand promissory notes for an aggregate purchase price of $25,000. The Net Capital Note will be convertible at the option of the holder at any time into shares of common stock, at a price equal to $0.05.
Simultaneously with the issuance of the Net Capital Note, the Company issued Net Capital a Series A Warrant to purchase 313,750 shares of common stock of the Company at a per share exercise price of $0.0625, and a Series B Warrant to purchase 313,750 shares of common stock of the Company at a per share exercise price of $0.075. The Series A Warrants and Series B Warrants are exercisable for up to seven years from the date of issue. Net Capital may exercise the Warrants on a cashless basis if the shares of common stock underlying the Warrants are not then registered pursuant to an effective registration statement. In the event Net Capital exercises the Warrants on a cashless basis, we will not receive any proceeds.
In September 2011, Investors converted $60,240 of the principal amount for 6,024,000 shares of the Companys common stock.
Financing Agreement
On November 8, 2010, the Company entered into a financing arrangement with Gemini Pharmaceuticals, Inc., a product development and manufacturing partner of the Company, pursuant to which Gemini Pharmaceuticals made a $250,000 strategic equity investment in the Company and agreed to make a $750,000 purchase order line of credit facility available to the Company.
The aggregate amount of outstanding Advances available to the Company under the Line of Credit may not exceed $750,000.00 at any time. The credit amounts available to the Company will be tiered, starting at $250,000 and will ramp up to $500,000 and then $750,000 upon achievement of determined milestones. The Advances requested under the Line of Credit may only be used for purchases of products and inventory from Gemini Pharmaceuticals.
The outstanding principal of all Advances under the Line of Credit will bear interest at the rate of interest of prime plus 2 percent per annum.
In partial consideration of the commitment made by Gemini Pharmaceuticals under the Line of Credit, the Company has issued to Gemini, non-callable 5-year warrants to purchase 300,000 additional shares of Common Stock at a share price of $0.12. The warrants contain a cashless exercise provision. The warrants vest as follows: 50% immediately, 25% when the credit line is increased to $500,000, and the remaining 25% when the credit line is increased to $750,000. At September 30, 2011, there were no borrowings under the agreement.
Joint Ventures
On March 1, 2011 the Company signed a term sheet that called for the formation of a joint venture with Engage:BDR to promote, market and sell online the Companys current and planned health and nutrition products.
The Company will agree to contribute up to $1,500,000 to the joint venture during the first year. Engage:BDR will agree to provide a full range of online marketing services to the joint venture, including developing brand strategy, the design of all digital media and interfaces, online media planning and buying, leveraging and integrating social media, and customer analysis. At September 30, 2011, the joint venture has not commenced its operations, and no contributions were made by either party pursuant to the agreement.
On June 29, 2011 the Company entered into a Joint Venture Agreement with John E. Repine, M.D. Under the terms of the Joint Venture Agreement, OXIS and Dr. Repine formed a Delaware limited liability company, Ergo ARDS, LLC (Ergo ARDS), in which OXIS holds a 60% membership interest and Dr. Repine holds a 40% membership interest. Ergo ARDS, LLC was formed to develop, acquire and market dietary supplements, cosmeceutical products, nutraceutical products, medical foods and pharmaceuticals using L-Ergothioneine for treating, diagnosing and preventing acute respiratory distress syndrome and other lung disorders (ARDS). Concurrently with the execution of the Joint Venture Agreement, Dr. Repine assigned his interest in the patent applications relating to the use of Ergo in treating ARDS to Ergo ARDS. In consideration for the assigned interest, Dr. Repine was issued a 40% membership interest in Ergo ARDS. OXIS will be responsible for supplying Ergo to Ergo ARDS at no cost in connection with Ergo ARDS animal studies. OXIS will also pay all patent prosecution and maintenance costs relating to the assigned intellectual property. Ergo ARDS is required to make payments to Dr. Repine upon the achievement of certain milestones by Ergo ARDS. Any future payments to Dr. Repine shall be made based on the achievement of following milestones: · Ergo ARDS shall pay the following cash amounts to Dr. Repine upon the attainment of the following milestones:
· Ergo ARDS shall pay the following cash amounts to Dr. Repine upon the attainment of the following milestones:
Following the successful completion of the animal studies, OXIS and Dr. Repine will make a joint decision to commence human clinical trials. If the parties do not agree to proceed, the Joint Venture Agreement will terminate and the intellectual property belonging to Ergo ARDS will be assigned to the party that elected to proceed. In the event both parties agree to not proceed, Ergo ARDS will continue to hold the intellectual property. If the parties agree to proceed, OXIS will use its best efforts to raise $3 million for Ergo ARDS. Once the $3 million in funds have been successfully raised by OXIS, OXIS will no longer be responsible for paying Ergo ARDS operating costs, including costs related to Ergo ARDS intellectual property. Ergo ARDS will be managed by Dr. Repine as Manager, Chief Executive Officer and Treasurer. Ergo ARDS will also have a board of five members, consisting of Dr. Repine and a designee of Dr. Repine, and three designees of OXIS.
|